MATRICS Consensus Cognition Battery

A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.

Authors: Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Grove RA, Horrigan JP, Jarskog LF, Kantrowitz JT, Keefe RS, Keshavan MS, Laurelle M, Lieberman JA, Lowy MT, Marder SR, Maruff P, McMahon RP, Peykamian MA, Seidman LJ

Journal: Schizophrenia Research

This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H3 receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7weeks (4weeks titration). […]

Back to Publications